Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1C | Q13936 | 8/20 | 0.83 |
| ▸ | MEN1 | O00255 | 6/20 | 0.83 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.83 |
| ▸ | CACNA1B | Q00975 | 3/20 | 0.83 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.83 |
| ▸ | MLNR | O43193 | 1/20 | 0.83 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.83 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.83 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.83 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.83 |
| ▸ | HTT | P42858 | 1/20 | 0.83 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.83 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.83 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.64 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.64 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.64 |
| ▸ | CYP2C19 | P33261 | 4/20 | 0.64 |
| ▸ | MAPT | P10636 | 4/20 | 0.64 |
| ▸ | LMNA | P02545 | 3/20 | 0.64 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cilnidipine SCHEMBL25551 | 0.91 | CACNA1C (1.00) | CACNA1CMEN1KMT2ACACNA1BADORA3 | |
| Cilnidipine SCHEMBL29367885 | 0.91 | CACNA1C (1.00) | CACNA1CMEN1KMT2ACACNA1BADORA3 | |
| Cilnidipine SCHEMBL31398437 | 0.91 | CACNA1C (1.00) | CACNA1CMEN1KMT2ACACNA1BADORA3 | |
| Cilnidipine SCHEMBL25550 | 0.91 | CACNA1C (1.00) | CACNA1CMEN1KMT2ACACNA1BADORA3 | |
| Cilnidipine SCHEMBL30209784 | 0.91 | CACNA1C (1.00) | CACNA1CMEN1KMT2ACACNA1BADORA3 | |
| Cilnidipine SCHEMBL3334757 | 0.91 | CACNA1C (1.00) | CACNA1CMEN1KMT2ACACNA1BADORA3 | |
| Cilnidipine SCHEMBL28356318 | 0.90 | CACNA1C (0.98) | CACNA1CMEN1KMT2ACACNA1BADORA3 | |
| Cilnidipine SCHEMBL29248832 | 0.90 | CACNA1C (0.98) | CACNA1CMEN1KMT2ACACNA1BADORA3 | |
| Cilnidipine SCHEMBL27852253 | 0.89 | CACNA1C (0.95) | CACNA1CMEN1KMT2ACACNA1BADORA3 | |
| Cilnidipine SCHEMBL29141421 | 0.86 | CACNA1C (0.90) | CACNA1CMEN1KMT2ACACNA1BADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 5876 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4741492-A2 | NECROSIS INHIBITOR | Linkgevity Limited (GB) | 2026-05-13 | — | — | EP | claimed |
| EP-4255391-B1 | LUMINOL FOR USE IN THE TREATMENT OF SEQUELAE OF A SARS-COV-2 INFECTION | METRIOPHARM AG (CH) | 2026-05-06 | — | — | EP | claimed |
| WO-2026090605-A2 | COMPOSITIONS AND METHODS COMPRISING TARGETED LIPOSOMAL THERAPEUTIC VACCINES | DREXEL UNIVERSITY (US) | 2026-04-30 | — | — | WO | claimed |
| EP-4691462-A1 | SILYBIN-CONTAINING COMPOSITION | Tianjin Tasly Sants Pharmaceutical Co., Ltd. (CN) | 2026-02-11 | — | — | EP | claimed |
| EP-4683634-A1 | TREATMENT OF SCLERODERMA | Aisa Pharma, Inc. (US) | 2026-01-28 | — | — | EP | claimed |
| EP-4648769-A2 | NECROSIS INHIBITOR | Linkgevity Limited (GB) | 2025-11-19 | — | — | EP | claimed |
| US-20250345332-A1 | APROCITENTAN FOR THE TREATMENT OF HYPERTENSION | IDORSIA PHARMACEUTICALS LTD (CH) | 2025-11-13 | — | — | US | claimed |
| US-12441687-B2 | Drp1-filamin complex formation inhibitors | Rdiscovery, LLC (US) | 2025-10-14 | — | — | US | claimed |
| EP-4615506-A1 | USE OF GSK-3 ACTIVATIOR TO MODULATE PROTEASOME ACTIVITY TO PREVENT AGEING ASSOCIATED CONDITIONS AND DISEASES | Sahin, Fikret (TR) | 2025-09-17 | — | — | EP | claimed |
| EP-4615577-A1 | METHODS OF TREATING EYE PAIN AND EYE DISORDERS | Aisa Pharma, Inc. (US) | 2025-09-17 | — | — | EP | claimed |
| EP-1303305-A2 | EPOXY-STEROIDAL ALDOSTERONE ANTAGONIST AND CALCIUM CHANNEL BLOCKER COMBINATION THERAPY FOR TREATMENT OF CONGESTIVE HEART FAILURE | Pharmacia Corporation (US) | 2003-04-23 | — | — | EP | claimed |
| US-20030073127-A1 | NOVEL CALCIUM CHANNEL DRUGS AND USES | THERAVANCE BIOPHARMA R&D IP, LLC | 2003-04-17 | — | — | US | claimed |
| US-20030073670-A1 | Stabilized pharmaceutical compositions containing a calcium channel blocker | SANKYO COMPANY, LIMITED (JP) | 2003-04-17 | — | — | US | claimed |
| WO-2002087556-A9 | PROBUCOL MONOESTERS AND THEIR USE TO INCREASE PLASMA HDL CHOLESTEROL LEVELS AND IMPROVE HDL FUNCTIONALITY | ATHEROGENICS INC (US) | 2003-03-20 | — | — | WO | claimed |
| US-20030055027-A1 | Epoxy-steroidal aldosterone antagonist and calcium channel blocker combination therapy for treatment of congestive heart failure | G. D. SEARLE & CO. (US) | 2003-03-20 | — | — | US | claimed |
| EP-1285655-A1 | STABILIZED PHARMACEUTICAL COMPOSITIONS CONTAINING CALCIUM CHANNEL BLOCKERS | Sankyo Company, Limited (JP) | 2003-02-26 | — | — | EP | claimed |
| WO-2002087556-A2 | PROBUCOL MONOESTERS AND THEIR USE TO INCREASE PLASMA HDL CHOLESTEROL LEVELS AND IMPROVE HDL FUNCTIONALITY | ATHEROGENICS, INC. (US) | 2002-11-07 | — | — | WO | claimed |
| WO-2002060461-A1 | BLOOD BRAIN BARRIER MODULATION USING STRESSED AUTOLOGOUS BLOOD CELLS | VASOGEN IRELAND LIMITED (IE) | 2002-08-08 | — | — | WO | claimed |
| US-20020042405-A1 | Epoxy-steroidal aldosterone antagonist and calcium channel blocker combination therapy for treatment of congestive heart failure | SCHUH JOSEPH R (US) | 2002-04-11 | — | — | US | claimed |
| WO-2002009761-A2 | EPOXY-STEROIDAL ALDOSTERONE ANTAGONIST AND CALCIUM CHANNEL BLOCKER COMBINATION THERAPY FOR TREATMENT OF CONGESTIVE HEART FAILURE | PHARMACIA CORPORATION (US) | 2002-02-07 | — | — | WO | claimed |